First-ever RNA editing trial in US gets clearance, pitting ‘exon editing’ technology against vision lossRyan CrossSenior Science CorrespondentThe FDA told the Boston startup Ascidian Therapeutics that it can begin the first clinical tests of a therapy that “rewrites” RNA to correct roughly two-thirds of the genetic typos responsible for an inherited form of vision loss...